Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01056315 · ClinicalTrials.gov registry record · Phase 2
A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y
A Phase 2 study, sponsored by Grünenthal.
- Terminated
- Registry status
- Phase 2
- Development phase
- 553
- Enrollment target
NCT01056315 is a Phase 2 study that was terminated before completion, run by Grünenthal. The registered enrollment target is 553 participants.
The verdict
NCT01056315, a Phase 2 study, was terminated before completion, sponsored by Grünenthal.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 553 participants
- Enrollment target
Study Summary
This trial is assessing the analgesic efficacy and safety of a new central analgesic in subjects with pain due to diabetic peripheral neuropathy (DPN).
Interventions
- DRUG Placebo
- DRUG GRT3938Y
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 553 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01056315
The ClinicalTrials.gov registry entry for NCT01056315 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 553 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grünenthal, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01056315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01056315 about?
NCT01056315 is a clinical study titled "A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y". This trial is assessing the analgesic efficacy and safety of a new central analgesic in subjects with pain due to diabetic peripheral neuropathy (DPN).
What is the current status of trial NCT01056315?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 553 participants. The study started on 2009-11. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01056315?
The interventions under investigation include: Placebo (DRUG), GRT3938Y (DRUG).
Who is sponsoring clinical trial NCT01056315?
This trial is sponsored by Grünenthal, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.